Skip to Main Content

Hello, everyone, and welcome to another working week. We hope the weekend respite was refreshing and relaxing because, once again, we have returned to that oh-so-familiar routine of meetings, deadlines, and the like. But you knew this would happen. How could it not? The world keeps spinning, no matter how much we desire to hit the pause button. So fire up the coffee kettle on this frosty morning and join us for a cup of stimulation as we dig in for another busy day. Hope your own journey goes smoothly and, as always, keep us in mind when something fascinating occurs …

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) will cut the price of their Praluent cholesterol drug by 60 percent to $5,850 a year, matching an unprecedented move that Amgen (AMGN) made last year with its own Repatha treatment, STAT writes. The companies, whose injectable drugs both had a list price of $14,000 per patient per year and were once expected to generate more than $1 billion in annual sales, have struggled as insurers and pharmacy benefit managers have made it difficult for patients to get the medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!